Other alterations in this gene included missense mutations and possible deletions on chromosome X. Since KDM6A loss has been shown to sensitize cancer cells to EZH2 inhibition (for example to FDA-approved tazemetostat) (61) and most of our patients were men, further studies would be desirable. This evidence concerns the gene KDM6A and cancer.